• Does FibroScan Accurately Assess Liver Fibrosis?

Does FibroScan Accurately Assess Liver Fibrosis?

Vibration-controlled transient elastography (VCTE) with FibroScan can provide an accurate assessment of liver fibrosis in patients with chronic viral hepatitis, but operator-related and patient-related factors affect measurements, report 2 articles published in the April issue of Clinical Gastroenterology and Hepatology. The lowest levels of variation occur in patients with no

Read more
  • Who is on the Liver Transplant Waitlist?

Who is on the Liver Transplant Waitlist?

The number of adults with nonalcoholic steatohepatitis (NASH) waiting for liver transplants has almost tripled in the last 10 years, researchers report in the March issue of Gastroenterology. NASH is now the second leading liver disease of adults awaiting liver transplantation in the United States, the researchers found. The prevalence of nonalcoholic fatty

Read more
  • What are the Roles for Chemokines in Liver Disease?

What are the Roles for Chemokines in Liver Disease?

Sustained hepatic inflammation contributes to the progression of chronic liver diseases such as hepatitis C and non-alcoholic steatohepatitis. In the September issue of Gastroenterology, Fabio Marra and Frank Tacke review the roles of chemokines in liver inflammation and disease progression. In the liver, chemokines regulate the migration and activities of hepatocytes, Kupffer

Read more

Podcast: How Does Fatty Liver Affect Risk for Cardiovascular Disease?

Modification of risk factors for cardiovascular disease—particularly dyslipidemia—is required to reduce morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). In a Perspective article published in the July issue of Clinical Gastroenterology and Hepatology, Kathleen E. Corey and Naga Chalasani discuss the increased risk of cardiovascular disease among patients with NAFLD, and strategies

Read more

A New Drug for Diabetes and Fatty Liver Disease?

Obeticholic acid (OCA)—an agonist of the farnesoid X receptor (FXR)— increases insulin sensitivity and reduces markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), according to a study published in the September issue of Gastroenterology. Type 2 diabetes mellitus and

Read more

How Can the Gut Microbiota Contribute to Liver Disease?

Microbes that reside in colons of obese individuals produce many compounds that could contribute to development of non-alcoholic fatty liver disease (NAFLD) and other complications of obesity, according to a study published in the July issue of Clinical Gastroenterology and Hepatology. Microorganisms living in the human intestine (gut microbiota) affect

Read more

How Common is Portal Hypertension in Patients With NAFLD?

Patients with nonalcoholic fatty liver disease (NAFLD) are at risk for portal hypertension and esophageal varices, according to the September issue of Clinical Gastroenterology and Hepatology. The study also shows that factors such as advanced liver disease, type 2 diabetes, and obesity can be used to identify patients most likely

Read more